1334-TIGIT-IL-12 Fusion Protein for Tumor Immunotherapy

Paper Talk · Jul 25, 2026 · 23m

The research article introduces T-12, an innovative immunocytokine designed to treat solid tumors by fusing the IL-12 cytokine with an anti-TIGIT antibody fragment. This molecular design allows the therapy to selectively target and activate natural killer (NK) and CD8+ T cells directly within the tumor microenvironment. By localizing the potent effects of IL-12 to the malignancy, the researchers successfully reduced the systemic toxicity typically associated with wild-type cytokine treatments. Experimental results demonstrate that T-12 effectively suppresses checkpoint-resistant tumors…